Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 44NIH 6NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma 12Leukemia 12Neuroblastoma 8Multiple Myeloma 6Myelodysplastic Syndromes 5Central Nervous System Neoplasms 5Brain Neoplasms 5Lymphoma, Follicular 4Leukemia, Myeloid, Acute 4Leukemia, Lymphocytic, Chronic, B-Cell 4Hodgkin Disease 4Teratoma 3Neoplasms, Plasma Cell 3Lymphoma, Large B-Cell, Diffuse 3Leukemia, Myelomonocytic, Chronic 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Leukemia, Monocytic, Acute 3Immunoglobulin Light-chain Amyloidosis 3Congenital Abnormalities 3Burkitt Lymphoma 3Waldenstrom Macroglobulinemia 2Recurrence 2Preleukemia 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Precancerous Conditions 2Ovarian Neoplasms 2Neoplasms by Histologic Type 2Neoplasms 2Myeloproliferative Disorders 2Lymphoproliferative Disorders 2

Interventions

Doxorubicin 4Cyclophosphamide 4Vincristine 3Rituximab 3Prednisone 3Dexamethasone 3Radiotherapy 2Peripheral Blood Stem Cell Transplantation 2Melphalan 2Interferon-alpha 2Etoposide 2Cytarabine 2Bortezomib 2tositumomab I-131 1liposomal amphotericin B 1fludarabine 1denileukin diftitox 1Watchful Waiting 1Vancomycin 1VAP-cyclo protocol 1Thalidomide 1Tazobactam 1Piperacillin, Tazobactam Drug Combination 1Piperacillin 1Palliative Care 1Nutritional Support 1Moxifloxacin 1Morphine 1Methotrexate 1Lapatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NETWORK × Waldenstrom Macroglobulinemia × Peripheral Blood Stem Cell Transplantation × Clear all
NCT00003416 2015-03-06

S9805, High-Dose Melphalan Plus Peripheral Stem Cell Transplantation Followed by Interferon Alfa in Treating Patients With Waldenstrom's Macroglobulinemia

SWOG Cancer Research Network

Phase 2 Completed
9 enrolled
Lymphoid

Lymphoma, Waldenstrom Macroglobulinemia

NCT00723658 2015-03-06

S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia

SWOG Cancer Research Network

Phase 2 Withdrawn
Lymphoid

Lymphoma, Waldenstrom Macroglobulinemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡